Clinical Trial Update: Safety, Tolerability, and Pharmacokinetics of CAT-192 (Human Anti-TGF-Beta1 Monoclonal Antibody) in Patients With Early Stage Diffuse Systemic Sclerosis [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/Phase 2 clinical trial update reports safety, tolerability, and pharmacokinetics data for CAT-192, a human anti-TGF-beta1 monoclonal antibody, in pati…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Diffuse Cutaneous Systemic Sclerosis
• Systemic Sclerosis

Drugs mentioned

• CAT-192

Snippet

Sponsor: Genzyme, a Sanofi Company | Conditions: Systemic Sclerosis, Scleroderma | Phase 1, Phase 2 | Status: COMPLETED